NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for Aeterna Zentaris INC


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


Refine Search
Display Mode: Context | Summary
AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
2009 JUN 22 ... AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine ...
Subject: Hormones
Price: $3.00
*
AEterna Zentaris Partner Keryx Reports Positive Phase 2 Data for Perifosine (KRX-0401) in Colon and Kidney Cancer at ASCO Meeting
2009 JUN 15 ... rstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine ...
Subject: Colon Cancer
Price: $3.00
*
AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
2009 JUN 15 ... AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine ...
Subject: Prostate Cancer
Price: $3.00
*
AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
2009 MAY 4 ... AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine ...
Subject: Lymphoma
Price: $3.00
*
AEterna Zentaris Receives US$10 Million from Institutional Investors
2009 JUL 6 ... AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine ...
Subject: Biotechnology Business
Price: $3.00
*
AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
2009 MAY 11 ... AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine ...
Subject: Biotechnology Business
Price: $3.00
*
AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
2009 MAR 23 ... AEterna Zentaris Inc. (NASDAQ:AEZS)(NASDAQ:TSX:)(NASDAQ:AEZ) ("the Company"), a global ...
Subject: Clinical Trial Research
Price: $3.00
*
AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results
2009 NOV 23 ... AEterna Zentaris Inc. (NASDAQ:AEZS)(NASDAQ:TSX:)(NASDAQ:AEZ) (the "Company"), a global biopharmaceutical ...
Subject: Biopharmaceuticals
Price: $3.00
*
AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
2009 APR 27 ... AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine ...
Subject: Biotechnology Business
Price: $3.00
*
AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
2009 NOV 2 ... AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused ...
Subject: Biotechnology Business
Price: $3.00
*
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
2009 JUN 29 ... AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine ...
Subject: Prostatic Hyperplasia
Price: $3.00
*
AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
2009 JUL 20 ... AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine ...
Subject: Alcoholism
Price: $3.00
*
Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
2009 SEP 28 ... 3 study by year-end." KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. in the United States, Canada and Mexico. Keywords: ...
Subject: Myeloma
Price: $3.00
*
Prostate Cancer Therapeutics - Global Strategic Business Report for Prostate Cancer Therapeutics in US$ Millions of Dollars
2009 JUN 8 ... companies including many key and niche players worldwide such as Abbott Laboratories, AEterna Zentaris Inc., ALZA Corporation, Amgen Inc., AstraZeneca PLC., Medimmune, LLC, Bristol-Myers Squibb ...
Subject: Research and Markets
Price: $3.00
*
Rodman & Renshaw Announces AEterna Zentaris to Raise $5.5 Million from Institutional Investors at $1.20 Per Share
2009 NOV 2 ... Rodman & Renshaw, LLC (NASDAQ: RODM) announced that its client AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine ...
Subject: Rodman & Renshaw, LLC
Price: $3.00
*
Sanofi-aventis and AEterna Zentaris Sign Agreement in the U.S.
2009 MAR 16 ... Sanofi-aventis U.S. announced the signing of an agreement with AEterna Zentaris GmbH for the development, registration and marketing of cetrorelix pamoate, a ...
Subject: sanofi-aventis U.S.
Price: $3.00
*
terna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2009 AUG 17 ... Actions, Therapies, Therapy, Treatment, U.S. Food and Drug Administration, Velcade, Aeterna Zentaris INC. This article was prepared by Biotech Business Week editors from staff and ...
Subject: Myeloma
Price: $3.00
*
terna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2009 AUG 24 ... Pharmaceuticals, Small Cell Lung Cancer, Solid Cancers, Solid Carcinomas, Therapies, Aeterna Zentaris INC. This article was prepared by Biotech Business Week editors from staff and ...
Subject: Cancer
Price: $3.00
*
terna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
2009 AUG 17 ... be available for a period of 30 days on the Company's website. Keywords: Aeterna Zentaris INC., Biopharmaceuticals, Drugs, Therapies, Pharmaceuticals, Oncology, Treatment, Therapy, ...
Subject: Aeterna Zentaris INC.
Price: $3.00
*
terna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
2009 SEP 14 ... be available for a period of 30 days on the Company's website. Keywords: Aeterna Zentaris INC., Biopharmaceuticals, Drugs, Therapies, Pharmaceuticals, Oncology, Treatment, Therapy, ...
Subject: Aeterna Zentaris INC.
Price: $3.00
*

Results 1 - 20      Next >




-----------------------
PR Login